-
Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.
-
Scribe Therapeutics cofounder and CEO Ben Oakes joins a16z Bio + Health founding general partner Vijay Pande.
-
Today's episode features the cofounders of Tome Biosciences, Rahul Kakkar, CEO of Tome, and John Finn, CSO. They are joined by Jorge Conde, general partner at a16z Bio + Health.
-
We have long believed that AI will fundamentally reshape biotech and healthcare, positioning us at the brink of an AI-driven Industrial Revolution. But when will we see this payoff? Put more boldly, when will the majority of new drugs be designed with AI?
-
All this to say—it’s time to figure out how to access, pay for, and deliver curative therapies (amongst other high-cost, complex, specialty drugs), at scale. Let’s dive into the specific challenges that need to be surmounted to get this right.
-
Today’s landmark approval by the US Food and Drug Administration of Vertex Pharmaceuticals’ and CRISPR Therapeutics’ EXA-cell, the world’s first CRISPR-based treatment, marks a groundbreaking shift in how we tackle intractable diseases.
-
Jordi Mata-Fink, PhD, cofounder of Gate Bioscience, joins Vineeta Agarwala and Ben Portney of a16z Bio + Health.In this episode, Jordi discusses how he and his cofounders are working to commercialize a novel class of therapeutics, termed "molecular gates."
-
Each new modality needs to find its platform-disease fit—the diseases it is uniquely suited for. But finding fit has increasingly turned into a fight; many have crowded into the same indications. With an expanding arsenal to treat disease, how will patients, clinicians, and the market determine what tool to use?
-
Olga Troyanskaya, PhD, a professor in the department of computer science at Princeton and Deputy Director for Genomics at the Flatiron Institute's Center for Computational Biology, joins Vijay Pande, founding partner of a16z Bio + Health.